Stem Cell Therapy in Heart Diseases - Cell Types, Mechanisms and Improvement Strategies

被引:158
|
作者
Mueller, Paula [1 ,2 ]
Lemcke, Heiko [1 ,2 ]
David, Robert [1 ,2 ]
机构
[1] Rostock Univ, Med Ctr, Dept Cardiac Surg, Reference & Translat Ctr Cardiac Stem Cell Theray, Rostock, Germany
[2] Rostock Univ, Dept Life Light & Matter, Interdisciplinary Fac, Rostock, Germany
关键词
Mesenchymal stem cells; Cardiovascular diseases; Cell replacement; Cardiac regeneration; Stem cell modification; ACUTE MYOCARDIAL-INFARCTION; LEFT-VENTRICULAR FUNCTION; BONE-MARROW-CELLS; CARDIAC PROGENITOR CELLS; SKELETAL MYOBLAST TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; NONISCHEMIC DILATED CARDIOMYOPATHY; CARDIOSPHERE-DERIVED CELLS; COLONY-STIMULATING FACTOR; HUMAN ADIPOSE-TISSUE;
D O I
10.1159/000492704
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
A large number of clinical trials have shown stem cell therapy to be a promising therapeutic approach for the treatment of cardiovascular diseases. Since the first transplantation into human patients, several stem cell types have been applied in this field, including bone marrow derived stem cells, cardiac progenitors as well as embryonic stem cells and their derivatives. However, results obtained from clinical studies are inconsistent and stem cell-based improvement of heart performance and cardiac remodeling was found to be quite limited. In order to optimize stem cell efficiency, it is crucial to elucidate the underlying mechanisms mediating the beneficial effects of stem cell transplantation. Based on these mechanisms, researchers have developed different improvement strategies to boost the potency of stem cell repair and to generate the "next generation" of stem cell therapeutics. Moreover, since cardiovascular diseases are complex disorders including several disease patterns and pathologic mechanisms it may be difficult to provide a uniform therapeutic intervention for all subgroups of patients. Therefore, future strategies should aim at more personalized SC therapies in which individual disease parameters influence the selection of optimal cell type, dosage and delivery approach. (C) 2018 The Author(s) Published by S. Karger AG, Basel
引用
收藏
页码:2607 / 2655
页数:49
相关论文
共 50 条
  • [31] Stem cell therapy for heart failure
    Angert D.
    Houser S.R.
    Current Treatment Options in Cardiovascular Medicine, 2009, 11 (4) : 316 - 327
  • [32] Stem Cell Therapy for Heart Disease
    Shannon B. Puliafico
    Marc S. Penn
    Kevin H. Silver
    Journal of General Internal Medicine, 2013, 28 : 1353 - 1363
  • [33] Stem Cell Therapy for Heart Failure
    Michler, Robert E.
    CARDIOLOGY IN REVIEW, 2014, 22 (03) : 105 - 116
  • [34] Stem Cell Therapy for Heart Failure
    Patel, Amit N.
    Silva, Francisco
    Winters, Amalia A.
    HEART FAILURE CLINICS, 2015, 11 (02) : 275 - +
  • [35] Stem cell therapy in the mouse heart
    Atsma, DE
    PHYSIOLOGICAL GENOMICS OF THE CRITICALLY ILL MOUSE, 2004, 16 : 349 - 361
  • [36] Cell Therapy for Respiratory Diseases: Optimizing Cell Delivery Strategies
    Karoubi, Golnaz
    Courtman, David W.
    Chiu, Ray C. J.
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2007, 3 (02) : 95 - 99
  • [37] Mesenchymal Stromal Cell Homing: Mechanisms and Strategies for Improvement
    Ullah, Mujib
    Liu, Daniel D.
    Thakor, Avnesh S.
    ISCIENCE, 2019, 15 : 421 - 438
  • [38] ADVANCED STEM CELL THERAPY FOR NEURODEGENERATIVE DISEASES
    Machado Ferreira, Helena Susana Costa
    Amorim, Diana
    Lima, Ana Claudia
    Pirraco, Rogerio P.
    Costa-Pinto, Ana Rita
    Almeida, Rui
    Almeida, Armando
    Reis, Rui L.
    Pinto-Ribeiro, Filipa
    Neves, Nuno M.
    TISSUE ENGINEERING PART A, 2023, 29 (11-12) : 613 - 614
  • [39] Importance of Stem Cell Therapy in Autoimmune Diseases
    Henes, J. C.
    Koetter, I.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2016, 75 (08): : 760 - 760
  • [40] Stem cell therapy in other cardiovascular diseases
    Ng, Kenneth
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2007, 122 : 15 - 16